SEC Form 4 · accession 0001209191-15-056346
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas K Bratton
10% Owner
Period of report
Jun 23, 2015
Accepted (ET)
Jun 25, 2015 · 4:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 23, 2015 | J | 825,726 | $0.00 | D | 492,669 | I | By JT Line Partners LP |
| Common StockF3,F2 | Jun 23, 2015 | S | 135,000 | $50.92 | D | 357,669 | I | By JT Line Partners LP |
| Common StockF4,F2 | Jun 24, 2015 | S | 135,000 | $51.33 | D | 222,669 | I | By JT Line Partners LP |
| Common StockF5,F6 | holding | — | — | — | 25,766,130 | I | By CL Alaska, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pro rata in-kind distribution of shares of Common Stock of Juno Therapeutics, Inc. (the "Issuer") from JT Line Partners LP ("JT") to limited partners of JT without consideration.
- F2The shares of the Issuer reported in Column 5 are held directly by JT. The general partner of JT is Bratton Capital Management L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. JT is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of the shares of the Issuer held by JT, as well as a partial pecuniary interest in such shares. JT directly beneficially owns these shares of the Issuer. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to indirectly beneficially own the shares of the Issuer held by JT. Each such entity and Mr. Bratton disclaim beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein.
- F3The price reported in Column 4 is a weighted average price. These shares reported as sold on June 23, 2015 were sold in multiple transactions at prices ranging from a low of $50.56 per share to a high of $51.37 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price set forth above and in footnote 4.
- F4The price reported in Column 4 is a weighted average price. The securities reported as sold on June 24, 2015 were sold in multiple transactions at prices ranging from a low of $50.65 per share to a high of $51.86 per share.
- F5These 25,766,130 shares of the Issuer are held directly by CL Alaska, L.P. ("CLA"). The general partner of CLA is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of CLA is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. CLA is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares of the Issuer, as well as a partial pecuniary interest in the shares held by CLA. Mr. Bratton does not intend to sell shares of the Issuer from CLA at this time, however, please see the related disclosures in Item 4 of the Schedule 13D/A filed on June 25, 2015. CLA may be deemed to directly beneficially own all of these shares of the Issuer.
- F6(Continued from Footnote 5) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to indirectly beneficially own all of these shares of the Issuer. Each such entity and Mr. Bratton disclaim beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein.